Madopar

Levodopa, the active ingredient in Madopar, is an antiparkinson agent presented as an oral tablet for oral use. It is combined with benserazide hydrochloride to treat Parkinson's disease and related Parkinsonian syndromes by restoring dopamine levels in the brain and reducing peripheral side effects.

GNH USA supplies Madopar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Madopar is an antiparkinson medication used to manage motor symptoms in disorders characterized by dopamine deficiency. - Parkinson's disease: improves rigidity, bradykinesia and tremor by increasing central dopamine. - Parkinsonian syndrome: alleviates motor deficits associated with secondary dopamine loss. - Secondary Parkinsonism: helps control symptoms when caused by drug‑induced or vascular factors.

Common Side Effects: - Nausea: gastrointestinal upset occurring early in therapy. - Dizziness: often related to orthostatic changes. - Headache: mild to moderate intensity. - Orthostatic hypotension: drop in blood pressure upon standing. - Insomnia: difficulty initiating sleep. - Dry mouth: reduced salivation.

Serious or Rare Side Effects: - Dyskinesia: involuntary movements with long‑term use. - Hallucinations: visual or auditory disturbances. - Severe hypotension: marked blood pressure decline requiring medical attention. - Neuroleptic malignant‑like syndrome: rare but life‑threatening reaction. - Severe depression or suicidal thoughts. - Cardiac arrhythmias: irregular heart rhythms in susceptible patients.

When prescribing Madopar, clinicians should consider several safety measures. - Dose titration: start low and increase gradually to minimize adverse effects. - Cardiovascular monitoring: watch for orthostatic hypotension and arrhythmias. - Neuropsychiatric assessment: monitor for hallucinations or mood changes. - Renal/hepatic impairment: adjust dosing in severe dysfunction. - Pregnancy and lactation: use only if benefits outweigh potential risks. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in the original packaging.

Madopar may interact with several drug classes, requiring careful management. Major Interactions (Avoid): - Non‑selective MAO inhibitors: risk of hypertensive crisis. - Anticholinergics: may reduce levodopa efficacy. - Iron supplements: decrease levodopa absorption. Moderate Interactions (Monitor Closely): - Selective MAO‑B inhibitors: may enhance dopaminergic effects. - Antihypertensives: additive hypotensive effect. - SSRIs/SNRIs: possible serotonin syndrome when combined with MAO inhibitors.